Markers of inflammation and microvascular complications in type 1 diabetes

Milena Mitrović 1 , Đorđe Popović 1 , Dragana Naglić 1 , Jovanka Paro 1 , Tatjana Ilić 2 , and Branka Zavišić 1
  • 1 Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia
  • 2 Clinic for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: role of inflammation. Indian J Med Sci 2007;61:292–306 http://dx.doi.org/10.4103/0019-5359.32098

  • [2] Kilpatrick ES, Keevil BG, Jagger C, Spooner RJ, Smalla M. Determinants of raised C reactive protein concentration in type 1 diabetes. Q J Med 2000;93:231–233 http://dx.doi.org/10.1093/qjmed/93.4.231

  • [3] Chase HP, Cooper S, Osberg I, Stene L, Barriga K, Norris J, et al. Elevated C reactive protein levels in the development of type 1 diabetes. Diabetes 2004;53:2569–2573 http://dx.doi.org/10.2337/diabetes.53.10.2569

  • [4] Devaraj S, Glaser N, Griffen S, Wang-Polgruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774–779 http://dx.doi.org/10.2337/diabetes.55.03.06.db05-1417

  • [5] Targher G, Zenari L, Bertoloini L, Muggeo G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular complications. Diabetes Care 2001;24:956–957 http://dx.doi.org/10.2337/diacare.24.5.956

  • [6] Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, et al. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 2009;52:1464–1473 http://dx.doi.org/10.1007/s00125-009-1401-0

  • [7] Pepys MB, Hirshfield GM. C reactive protein: a critical update. J Clin Invest 2003;111 (12):1805–12 http://dx.doi.org/10.1172/JCI200318921

  • [8] Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22 (5):347–352 http://dx.doi.org/10.1093/intimm/dxq030

  • [9] Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol 2011;239 (3):115–122 http://dx.doi.org/10.1007/s00232-010-9309-7

  • [10] Fraser GE, Luke R, Thompson S, Smith H, Carter S, Sharpe N. Comparison of echocardiographic variables between type I diabetics and normal control. Am J Cardiol 1995;75:141–145 http://dx.doi.org/10.1016/S0002-9149(00)80063-6

  • [11] Venugopal SK, Devaraj S, Jialal I. Effect of C reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14:33–37 http://dx.doi.org/10.1097/00041552-200501000-00006

  • [12] Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Lipowski P, Raczynska K. Relationship between serum levels of tumor necrosis factor-alpha and interleukin-6 in diabetes mellitus type 1 children. Centr Eur Immunol 2007;32 (3):124–128

  • [13] Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: Evidence for chronic inflammation. Diabetologia 1999;42:351–357 http://dx.doi.org/10.1007/s001250051162

  • [14] Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CDA. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370–378 http://dx.doi.org/10.1007/s00125-004-1628-8

  • [15] Chaturvedi N, Fuller JH, Taskinen MR. EURODIAB study group: Differing associations of lipid and lipoprotein disturbances with macrovascular and microvascular complications of type 1 diabetes. Diabetes Care 2001;24:2071–2077 http://dx.doi.org/10.2337/diacare.24.12.2071

  • [16] Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR et al. C reactive protein, insulin resistance, central obesity and coronary heart disease risk in Indian Asians from United Kingdom compared with Europian whites. Circulation 2001;104:145–150 http://dx.doi.org/10.1161/01.CIR.104.2.145

  • [17] Jurisic V, Terzic T, Colic S, M Jurisic. The concentration of TNF-α correlate with number of inflammatory cells and degree of vascularization in radicular cysts. Oral Dis 2008;14(7):600–605 http://dx.doi.org/10.1111/j.1601-0825.2007.01426.x

  • [18] Lopes Virella MF, Carter RE, Gilbert GE, Klein RL, Jaffa M, Jenkins A. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 2008;31:2006–2012 http://dx.doi.org/10.2337/dc08-0659

  • [19] Ladeia AM, Stefanelli E, Ladeia-Frota C, Moreira A, Hiltner A, Adan L. Association between elevated serum C reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care 2005;29 (2):424–426

  • [20] Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48–58 http://dx.doi.org/10.1056/NEJMra021678

  • [21] Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053 http://dx.doi.org/10.3109/02713689508998529

  • [22] Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophtalmol Vis Sci 2001;42:1586–1591

  • [23] Skundric DS, Robert P. Role of neuropoetic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Experimental Diab Res 2003;4:303–312 http://dx.doi.org/10.1155/EDR.2003.303

  • [24] Herder C, Lankish M, Ziegler D, Rathmann W, Koenig W, Illig T, et al. Subclinical inflammation and diabetic polyneuropathy. Diabetes Care 2009;32 (4):680–682 http://dx.doi.org/10.2337/dc08-2011

  • [25] Haaber AB, Deckert M, Stender S, Jensen T. Increases urinary loss of high density lipoproteins in albuminuric insulin dependent diabetic patients. Scand J Clin Lab Invest 1993;53:191–196 http://dx.doi.org/10.3109/00365519309088407

  • [26] Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A: cholesterol acyltransferase (ACTA) in nephritic syndrome. Kidney Int 2002;62 (5):1769–1775 http://dx.doi.org/10.1046/j.1523-1755.2002.00319.x

  • [27] Gedela S, Guruju VPB, Sulakshana M, Meheswari IL, Prabhakar T, Sankar G, et al. Quantitative analysis of cytokines in diabetic nephropathy. Journal Proteomics Bioinform 2009;2:217–221 http://dx.doi.org/10.4172/jpb.1000079

  • [28] Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hyperholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000;11:669–683

  • [29] Rivellese AA, Vaccuaro O, Patti L. The patophysiology of lipid metabolism and diabetes. Int J of Clin Pract 2004;58:32–35 http://dx.doi.org/10.1111/j.1368-504X.2004.00332.x

  • [30] Schram M, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, et al. The EURODIAB Prospective Complications Study Group: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care 2003;26 (7):2165–2173 http://dx.doi.org/10.2337/diacare.26.7.2165

  • [31] Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, et al. Lipid and lipoprotein pro-files in youth with and without type 1 diabetes. The search for diabetes in youth case-control study. Diabetes Care 2009;32(3):416–420 http://dx.doi.org/10.2337/dc08-1775

OPEN ACCESS

Journal + Issues

Search